Abstract 907: XMT-1660, a B7-H4-targeted Dolasynthen antibody-drug conjugate for the treatment of breast cancer

Fessler, Shawn P.; Wang, Jason; Collins, Scott D.; Qin, LiuLiang; Avocetien, Kenneth; Xu, Ling; Eydelloth, R. S.; Vonderfecht, Steven; Chin, Chen-Ni; Bradley, Steven M; Clardy, Susan; Dirksen, Anouk; Ditty, Elizabeth; Du, Bingfan; Kim, Dokyong; Mosher, Rebecca; Ter-Ovanesyen, Elena; Slocum, Kelly L.; Uttard, Alex; Wongthida, Phonphimon; Zurita, Jeffrey; Toader, Dorin; Damelin, Marc; Lowinger, Timothy B.

doi:10.1158/1538-7445.am2021-907

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…XMT-1660, an antibody-drug conjugate in the composition of an anti-B7-H4 antibody conferring great link-coupled specificity. It has been confirmed consistently showed more significant anti-tumor ability in the model within the organism in breast cancer [40] . Thus, immunosuppressive agents targeting VTCN1 will benefit more patients.…”

Section: Experimental Verificationsupporting

confidence: 55%

A Pan-Cancer Analysis Indicates the Prognostic Significance and Immunological Function of V-Set Domain Containing T-Cell Activation Inhibitor 1

Yu,

feng,

et al. 2023

IJPS

View full text Add to dashboard Cite

The immune costimulatory protein V-set domain containing T cell activation inhibitor 1 is a key molecule in the B7 family developing advanced growth in multiple cancers as a suppressive regulatory factor during T cell immunoreaction. For the purpose of confirming the importance of prognosis and ascertaining the effects on tumor immunity of V-set domain containing T cell activation inhibitor 1 gene expression across diverse cancers. The design utilized a wide range of tools involved in bioinformatics from the available public database to integrally identify the association between V-set domain containing T cell activation inhibitor 1 and prognosis, clinic pathological features, tumor mutational burden, microsatellite instability, methyl transferase, mismatch repair, immune cell permeation among different tumors, chemotherapy drug sensitivities, and try to comprehensively probe potentially carcinogenic of V-set domain containing T cell activation inhibitor 1. The results exhibited that V-set domain containing T cell activation inhibitor 1 was overexpressed in various tumor types. As an independent risk factor for the prognosis of 12 different cancer types, V-set domain containing T cell activation inhibitor 1 expression had a connection with survival status. Additionally, it is advantageous in 15 different cancer types for diagnosis. Meanwhile, in 10 and 7 cancer types, the expression of V-set domain containing T cell activation inhibitor 1 was distinctly correlated to tumor mutational burden and microsatellite instability. And the close connection of V-set domain containing T cell activation inhibitor 1 with immune cell infiltration was considered, especially T cells cluster of differentiation 8+, T cells cluster of differentiation 4+, neutrophils, myeloid dendritic cells, macrophages and B cells within most types of cancer. The implication of V-set domain containing T cell activation inhibitor 1 showed the valuable prognostic potentiality in multiple cancers, and it may function as an immunotherapy target in multiple malignant tumors according to the impact on tumorigenesis and tumor immunity.

show abstract

Section: Experimental Verificationsupporting

confidence: 55%